Order-of-magnitude gap: the company is already serving a demand source whose scale dwarfs its own current business
The model's full reasoning — Q2 2023 call → NOWe need to determine if management describes a mismatch of scale between the company and the demand it is already serving. The key is: the company is already inside a large flow, and management explicitly draws the size contrast, treating it as a point. Looking at the transcript, there are several mentions of large opportunities, but we need to see if it's about current participation and a size contrast. - They talk about the Salesforce partnership: "We onboarded a record 176 logos in Q2 and we continue to expect contributions to grow meaningfully and linearly over the course of 2023 building to a very strong Q4 as the largest and most complex deployments begin to make their migration over to Sprout." This is about a partnership, but it's not necessarily a mismatch of scale relative to the company's size. They are serving customers, but the contrast is not explicit. - They talk about the influencer marketing acquisition: "We believe the cross-sell opportunity for Tagger’s product is massive in orders of magnitude larger than Tagger today." That is a size contrast, but is it about the company already being inside? They just acquired Tagger, so they are now inside influencer marketing. But the statement is about cross-sell opportunity, which is prospective. They say "we believe" and "orders of magnitude larger" but it's about future potential, not current activity. Also, they say "we have made no cross-selling assumptions" so it's not yet realized. - They talk about the overall market: "We have introduced our new medium-term financial plan expect to exceed $1 billion in subscription revenue in 2028." That's a target, not a current mismatch. - They mention "record new business ACVs" and "ACV growth to a record 29% year-over-year" but that's about their own growth, not a mismatch. - They talk about the low end of the business being unpredictable and they are removing it from forecast. That's not a mismatch. - They talk about "enterprise grew nearly 50% year-over-year and represents a record 43% of total ARR." That's about their own growth. - They mention "influencer marketing in more than half of our enterprise RFPs" but that's about demand, not about being inside a large flow.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| GDRX | GoodRx Holdings, Inc. | Q2 2022 | 2022-08-08 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
HROW · Q4 2021 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript shows management describing Harrow as already inside the large cataract surgery market (4.5–6 million procedures annually) with real, present-tense participation: thousands of customer relationships, shipping north of two million sterile ophthalmic units last year, and touching roughly one million cataract surgeries. They explicitly contrast this scale against 2021 revenues of $72.5 million, noting that even a modest share of the pass-through-eligible market (1 million procedures × premium pricing) would produce “a big number” and drive revenues “more than double” in the near term. They treat the current business as only the “earliest sliver” of what they are already positioned inside, with the binding question being how much of the existing flow they can capture rather than whether the flow exists. This meets both criteria. The answer is YES. The transcript shows management describing Harrow as already inside the large cataract surgery market (4.
WRBY · Q1 2024 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript explicitly states that the company is already inside the optical industry with real business (245 stores serving customers, 83% of stores offering exams, 2.36 million active customers, and growing revenue from glasses, contacts, and exams). Management then draws the size contrast directly, noting that even the longer 900-store target "would still represent a small fraction of the 45,000 optical shops in the U.S." and that over 50% of major metro areas have only one store.
HSTM · Q3 2017 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...**YES** Management describes the company already being inside a much larger flow of activity (the 80 million-person healthcare workforce, of which 4.6 million are in post-acute settings) and explicitly treats the scale mismatch as the central point. They note their strong sales team is already a “steady contributor” to 4.